NCT05261360

Clinical Efficacy of Exosome in Degenerative Meniscal Injury

A Phase II Trial to Investigate Clinical Efficacy of Autologous Synovial Fluid Mesenchymal Stem Cell-Derived Exosome Application in Patients With Degenerative Meniscal Injury

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Eskisehir Osmangazi University · Academic / Other
• Sex: All
• Age: 30 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Comparison of intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes with synovial fluid-derived mesenchymal stem cells on the same patient.

Detailed description

Mesenchymal stem cell-derived exosomes will be developed and patented as an advanced technology platform as an autologous treatment protocol to repair damaged cartilage tissue. The fact that this treatment is obtained from an autologous source will significantly contribute to the literature in the field of personalized therapy (personalized medicine) and will pave the way for discoveries. Experiences from clinical trials may guide the use of MSC exosomes in other tissue and cell damaged pathologies and immune pathologies or chronic inflammatory diseases. This study was supported by a grant (1004, 20AG031) from The Scientific and Technological Research Council of Turkey (TUBITAK).

Conditions

• Knee; Injury, Meniscus (Lateral) (Medial)
• Meniscus Tear
• Meniscus Lesion
• Meniscus; Degeneration
• Meniscus; Laceration
• Meniscus Injury, Tibial
• Knee Injuries
• Knee Pain Swelling
• Arthralgia

Interventions

Type	Name	Description
DRUG	SF-MSC-EX	Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
DRUG	SF-MSC	Intra-articular administration of synovial fluid-derived mesenchymal stem cells

Timeline

• Start date: 2022-03-01
• Primary completion: 2024-03-01
• Completion: 2025-03-01
• First posted: 2022-03-02
• Last updated: 2022-03-04

Locations

1 site across 1 country: Turkey (Türkiye)